West Lafayette, Indiana, United States, December, 2024 – On Target Laboratories, Inc., a biotechnology company specializing in intraoperative molecular imaging agents to target and illuminate cancer during surgery, has announced the appointment of Bill Peters as President and Chief Executive Officer (CEO). Peters has also joined the company’s board of directors, succeeding Ben Lundgren, who served as CEO since 2023.
Scott Huennekens, Executive Chairperson of the Board at On Target Laboratories, remarked, “Ben has been a pivotal force in advancing the commercialization of CYTALUX, building our Sales and Marketing organization, establishing strategic partnerships, and forging key customer relationships. We are deeply grateful for his leadership. We are excited to welcome Bill as our new CEO. His impressive track record of driving success at large organizations uniquely positions him to scale On Target and continue delivering value for both our customers and investors.”
Peters brings over 20 years of leadership experience in the medical technology sector. Most recently, he served as President of the Advanced Surgical and Advanced Endoscopic Technologies businesses in ConMed’s General Surgery division, where he drove substantial sales and profit growth. His tenure included leading three successful acquisitions and launching innovative products. Previously, Peters held senior commercial roles at Mako Surgical Corporation, Intuitive Surgical, and Stryker Corporation. He holds a Bachelor of Business Administration in Finance from Ohio University.
Peters expressed his enthusiasm, stating, “I am both honored and excited to take on this leadership role at such an impactful company. The work we are doing to provide patients with groundbreaking technology and renewed hope is incredibly inspiring. I look forward to working alongside our exceptional team to advance our mission to illuminate cancer intraoperatively so it can be removed completely.”
About On Target Laboratories, Inc.
On Target Laboratories discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery. Their molecular imaging technology, based on the pioneering work of Philip S. Low, PhD, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, combines a near-infrared dye with a targeting molecule that binds to receptors overexpressed on cancer cells. This illumination technology enables surgeons to detect and remove more cancerous tissue that otherwise might have been left behind.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
